Syngene Adds Biologics Drug Substance Manufacturing Capacity with Facility Acquisition

Published on: 

Syngene has acquired a multi-modal biologics drug substance manufacturing facility in Bangalore, India, from Stelis Biopharma.

Integrated research, development, and manufacturing services company, Syngene, has acquired a multi-modal facility in Bangalore, India, from Stelis Biopharma, it was announced in a July 4, 2023 press release. The acquisition provides Syngene with an extra 20,000 L of installed biologics drug substance manufacturing capacity.

Originally built to manufacture COVID-19 vaccines, the acquired facility will now be repurposed and revalidated for the manufacture of monoclonal antibodies by Syngene. Additionally, the site, which includes a commercial-scale, high speed, fill/finish unit, has the potential for future expansion of a further 20,000 L capacity.

“This acquisition strengthens our growing position as a leading biologics contract development and manufacturing service provider and adds drug substance capacity and a drug product capability years earlier than our internal capex program,” said Jonathan Hunt, managing director and CEO of Syngene, in the press release. “We see healthy demand for high-quality biologics manufacturing capacity from sectors ranging from large pharma to emerging biotech companies.”


The transaction for the facility cost INR 702 Crores ($86 million) and has been approved by both companies’ boards of directors. Closure of the transaction is expected within 90 days, as long as the customary conditions are met.

Source: Syngene